.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cantor Fitzgerald
Colorcon
Farmers Insurance
McKesson
Teva
Federal Trade Commission
Mallinckrodt
Novartis
Queensland Health
Boehringer Ingelheim

Generated: September 24, 2017

DrugPatentWatch Database Preview

NATESTO Drug Profile

« Back to Dashboard

What is the patent landscape for Natesto, and what generic Natesto alternatives are available?

Natesto is a drug marketed by Aytu Bioscience Inc and is included in one NDA. There are four patents protecting this drug.

This drug has twenty-four patent family members in twenty-one countries.

The generic ingredient in NATESTO is testosterone. There are sixty-one drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the testosterone profile page.

Summary for Tradename: NATESTO

Patents:4
Applicants:1
NDAs:1
Suppliers / Packagers: see list2
Bulk Api Vendors: see list53
Clinical Trials: see list2
Patent Applications: see list9,770
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:NATESTO at DailyMed

Pharmacology for Tradename: NATESTO

Ingredient-typeAndrostanes
Drug ClassAndrogen
Mechanism of ActionAndrogen Receptor Agonists
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aytu Bioscience Inc
NATESTO
testosterone
GEL, METERED;NASAL205488-001May 28, 2014RXNoNo► Subscribe► SubscribeY ► Subscribe
Aytu Bioscience Inc
NATESTO
testosterone
GEL, METERED;NASAL205488-001May 28, 2014RXNoNo► Subscribe► Subscribe ► Subscribe
Aytu Bioscience Inc
NATESTO
testosterone
GEL, METERED;NASAL205488-001May 28, 2014RXNoNo► Subscribe► SubscribeY ► Subscribe
Aytu Bioscience Inc
NATESTO
testosterone
GEL, METERED;NASAL205488-001May 28, 2014RXNoNo► Subscribe► SubscribeY ► Subscribe
Aytu Bioscience Inc
NATESTO
testosterone
GEL, METERED;NASAL205488-001May 28, 2014RXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: NATESTO

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
2,014,073,618► Subscribe
9,579,280Controlled release delivery system for nasal applications and method of treatment► Subscribe
9,238,072Controlled release delivery system for nasal applications and method of treatment► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: NATESTO

Country Document Number Estimated Expiration
Denmark1530965► Subscribe
World Intellectual Property Organization (WIPO)2005044273► Subscribe
South Africa200603115► Subscribe
Germany60303854► Subscribe
South Korea100861443► Subscribe
CroatiaP20060147► Subscribe
Austria319426► Subscribe
Taiwan200515918► Subscribe
Slovenia1530965► Subscribe
Norway338665► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cerilliant
Merck
Deloitte
Chubb
Fish and Richardson
Teva
Chinese Patent Office
McKesson
Queensland Health
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot